Precision Care · Multidisciplinary Collaboration · Patient-Centered Services

Our care model emphasizes early recognition, continuous assessment, and individualized pharmacotherapy. Clinical evaluation, autoantibody testing, and musculoskeletal ultrasonography are used to identify joint inflammation and monitor disease activity. Treat-to-target strategies are tailored to treatment response, comorbidities, and medication-related risks. Our team conducts research on “Smart Anti-Inflammation”, a precision treatment-response prediction initiative exploring genetic and other biomarkers to inform targeted therapy selection. We have also established structured processes for comorbidity assessment, risk management, and longitudinal case follow-up, aiming to reduce disease burden, preserve physical function, and improve quality of life.

All patients with moderate-to-severe rheumatoid arthritis are enrolled in a structured case management program incorporating treat-to-target care and comprehensive comorbidity risk assessment. Disease activity, therapeutic effectiveness, and medication safety are regularly evaluated. Through multidisciplinary coordination, the team seeks to identify and manage cardiovascular disease, infection, osteoporosis, and other comorbidity risks early, while continually optimizing individualized treatment strategies. This approach aims to increase remission rates, limit joint damage, maintain physical function, and improve long-term quality of life.

1. Chen PK, Chen YM, Chen JJW, Chen DY. Anti-peptide antibodies, anti-SNRK and anti-HUWE1 antibodies as potential predictors of good response to tofacitinib therapy in rheumatoid arthritis patients. Rheumatology (Oxford). 2025 May 1;64(5):2451-2460.
2. Chen PK, Chen YM, Cho CF, Chen JJJW, Wu JC, Daf D, Gong NR, Chen DY. A panel incorporating genetic variants of RIN3, NLRC3, and SLX4 shows promise in predicting remission after tofacitinib therapy in rheumatoid arthritis patients. Clin Exp Rheumatol. 2025 Sep;43(9):1548-1553.
3. Chen PK, Chang SH, Chen YM, Chen HH, Huang PH, Huang CC, Yeo KJ, Lan JL, Chen DY. Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving Janus kinase inhibitors in a retrospective and observational study. Clin Rheumatol. 2024 Aug;43(8):2503-2511.
4. Chen YH, Su WJ, Hsieh SZ, Yu KH, Jan YJ, Lee SS, Wey JC, Chen JH, Chiu YM, Huang KY, Tsai WJ, Cheng JT, Cheng TT, Cheng CL, Chen DY. 2015 TRA revised recommendations for screening and management of tuberculosis infection in patients before and after anti-tumor necrosis factor-alpha biological treatment. Formosan Jo Rheumatol 2015;29:1-8.
5. Chen YH, Chieh RN, Huang YH, Chen DY*, Lan JL, Lu LY, Hsieh TY, Wey JC, Tsay GJ. Screening and management of hepatitis B infection in rheumatic patients scheduled for biologic therapy: consensus recommendations from the TRA. Formosan J Rheumatol 2012;26:1-7.

• 2018–2026: Recognized as an Asia Pacific League of Associations for Rheumatology (APLAR) Clinical Center of Excellence (Appendices 1 and 2).

• 2023: Received the “Center of Excellence” distinction under the National Healthcare Quality Award (NHQA) (Appendix 3).

• 2021–2023: Rheumatoid arthritis comorbidity care received the Symbol of National Quality (SNQ) certification in three consecutive years (Appendix 4).

• 2024–2026: The “Smart Anti-Inflammation” rheumatoid arthritis precision diagnostic initiative received the 2024 National Innovation Award, the 2025 Taipei Biotech Award, and the 2026 National Science and Technology Council Future Technology Award (Appendices 6–8).

​

Clinical team: Refer to the physicians currently listed on the center’s official website.

Appointments and patient information: Refer to the hospital’s official website.

Our center specializes in adult-onset Still’s disease and complex autoinflammatory disorders. For patients presenting with recurrent high fever, rash, arthritis, or unexplained systemic inflammation, we integrate clinical assessment, exclusion of infection and malignancy, laboratory testing, and multidisciplinary collaboration to facilitate timely and appropriate diagnosis. Our team has established standardized diagnostic and treatment pathways and interdisciplinary care processes, supported by patient education to promote long-term disease management. Our research explores emerging biomarkers, including inflammatory cytokines and gene-expression profiles, with the aim of translating these findings into earlier diagnosis, disease activity assessment, and personalized treatment.

Our center provides coordinated, one-stop diagnostic and treatment services for AOSD through multidisciplinary care. By combining standardized differential diagnosis, disease activity monitoring, assessment of severe disease risk, and patient education, we aim to streamline the diagnostic and care pathway for complex cases and strengthen continuity of long-term management.

1. Chang SH, Hsu TC, Huang PH, Huang CC, Yeo KJ, Hong WJ, Chen PK, Lin YH, Lan JL, Chen DY. A Streamlined Diagnostic Process Improved the Outcomes of Patients with Adult-Onset Still’s Disease: A Single-Center Retrospective Observational Study. Rheumatol Ther. 2023;10:343–355.
2. Chen PK, Lan JL, Huang PH, Hsu JL, Chang CK, Tien N, Lin HJ, Chen DY. Interleukin-18 Is a Potential Biomarker to Discriminate Active Adult-Onset Still’s Disease From COVID-19. Front Immunol. 2021;12:719544.
3. Yang CA, Chen PK, Lan JL, Chang CK, Chang JG, Chang SH, Lin CC, Chen DY. Expression signature of inflammation-associated long non-coding RNAs in adult-onset Still’s disease. Clin Exp Rheumatol. 2021;39 Suppl 132:67–74.

• 2022–2025: Awarded the Symbol of National Quality (SNQ) for AOSD care (Attachment 5).

• 2018–2026: Recognized as an APLAR Clinical Center of Excellence by the Asia Pacific League of Associations for Rheumatology (Attachments 1 and 2).

• 2023: Received the “Center of Excellence” distinction under the National Healthcare Quality Award (NHQA) (Attachment 3).

Medical team: Please refer to the physician profiles on the center’s current official website.

Appointments and patient information: Please refer to the hospital’s official website.

Our center has established an integrated multidisciplinary model involving rheumatologists, pulmonologists, radiologists, and other specialists. The team jointly evaluates patients and plans immunomodulatory therapy, antifibrotic treatment, and pulmonary rehabilitation, while monitoring longitudinal changes in lung function and imaging findings. We also incorporate research on emerging biomarkers and regenerative medicine to advance clinical care. In addition to leading rheumatology experts in Taiwan in developing recommendations for the diagnosis and management of rheumatoid arthritis–associated ILD, our center completed a Phase I/II clinical trial in 2026 evaluating allogeneic adipose-derived stem cell therapy for systemic autoimmune rheumatic diseases–associated ILD. According to the center’s preliminary report, the trial demonstrated a favorable safety profile; further evaluation is needed to establish efficacy.

Our center has established multidisciplinary diagnostic, treatment, and longitudinal follow-up pathways for systemic autoimmune rheumatic diseases–associated ILD. Patients assess their respiratory symptoms and severity through patient-reported outcome measures (PROMs). These assessments are integrated with clinical symptoms, thoracic imaging, and pulmonary function data to support earlier identification of pulmonary involvement and disease progression. Individualized treatment, medication-risk management, and cardiopulmonary rehabilitation form the basis of our comprehensive, patient-centered care.

1. Chang SH, Yeh FC, Chen PK, Yeo KJ, Huang CC, Huang PH, Wu PC, Lan JL, Chen DY. The presence of anti-Ro52/SSA antibodies may predict concomitant pulmonary hypertension and poorer survival in patients with connective tissue disease-associated interstitial lung disease. Clin Rheumatol. 2026 Jul;45(7):4369–4382.
2. Wang TD, Teo KF, Lan JL, Hsu JL. A non-radioactive modified immunoprecipitation assay for diagnostic detection of anti-MDA5 antibodies in idiopathic inflammatory myopathies. Front Immunol. 2026 Jul 15;17:1896104.
3. Ko CJ, Teo KF, Lai YH, Lan JL, Hsu JL. Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy. J Vis Exp. 2025 Oct 31;(224).
4. Cheng WC, Chang SH, Chen WC, Wu BR, Chen CH, Lin CC, Hsu WH, Lan JL, Chen DY. Application of impulse oscillometry to detect interstitial lung disease and airway disease in adults with rheumatoid arthritis. BMC Pulm Med. 2023 Sep 8;23(1):331.
5. Yu KH, Chen HH, Cheng TT, Jan YJ, Weng MY, Lin YJ, Chen HA, Cheng JT, Huang KY, Li KJ, Su YJ, Leong PY, Tsai WC, Lan JL, Chen DY. Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis. Medicine (Baltimore). 2022 Jan 7;101(1):e28501.

• 2018–2026: Recognized as an APLAR Clinical Center of Excellence by the Asia Pacific League of Associations for Rheumatology (APLAR). (Attachments 1 and 2)

• 2023: Received the “Center of Excellence” distinction under the National Healthcare Quality Award (NHQA). (Attachment 3)

Medical team: Please refer to the physician roster currently published on the hospital website.

Appointments and patient information: Please refer to the hospital’s official website.

Our center provides thorough clinical evaluation and individualized management for chronic spontaneous urticaria, refractory allergic disorders, severe allergic reactions, and suspected drug allergy. Assessments include detailed medical histories and analysis of symptoms and potential triggers. For patients with allergic diseases, disease activity and symptom control are evaluated regularly, with treatment escalated in a stepwise manner according to clinical need, including consideration of appropriate biologic therapy when indicated. For suspected drug allergy, clinicians review the timing and clinical features of reactions alongside medication histories, select appropriate diagnostic tests and alternative medications, and provide allergy risk counseling and medication safety guidance.

Our patient-centered approach includes assessment of disease control and long-term follow-up for chronic urticaria and complex allergic disorders. Patients with suspected drug allergy receive systematic history review, risk assessment, and guidance on safe medication use. Through individualized therapy and interdisciplinary communication, the center aims to reduce recurrent symptoms, prevent unnecessary medication avoidance, improve treatment safety, and enhance quality of life.

1. Wayal V, Lee MF, Wang JY, Chen YH. Gram-Positive and Gram-Negative Probiotic Extracellular Vesicles: Mechanisms of Immune Modulation and Therapeutic Opportunities in Atopic Dermatitis. Clin Rev Allergy Immunol. 2026 Sep 11;69(1):76.
2. Sheu HS, Chen YM, Chen JP, Juan CK, Huang WN, Chen YH, Tang KT. Drug persistence of omalizumab, cyclosporine, and hydroxychloroquine in antihistamine-refractory chronic spontaneous urticaria: A biomarker-stratified real-world study. Asian Pac J Allergy Immunol. 2026 Jul 29. doi: 10.12932/AP-260126-2221.
3. Lee MF, Wu CS, Lin TM, Li HF, Chen YH. Clinical manifestations and cross-reactions between cockroaches and termites and identification of termites’ major allergens. PLoS One. 2026 Mar 23;21(3):e0342319.

• 2018–2026: Recognition as an Asia Pacific League of Associations for Rheumatology (APLAR) Clinical Center of Excellence (Appendices 1 and 2).

• 2023: National Healthcare Quality Award (NHQA), Excellence Center (Appendix 3).

Medical team: Dr. Yi-Hsing Chen (Vice Superintendent, Rheumatology and Immunology Center; Director, Division of Allergy) and the multidisciplinary team at the hospital’s Rheumatology and Immunology Center.

Appointments and patient information: Please refer to the hospital’s official website.